Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

Gamma-Neutron Vision aimed at improved cancer treatments in Hadron Therapy

Objectif

Proton therapy represents one of the most recent and adavanced tools in cancer treatment, especially for complex cases and pediatric patients. Despite its exponential deployment worldwide, hadron therapy still faces two main limitations, which are related to: i) accurate ion-range verification and ii) assessment of the secondary (unwanted) neutron dose. The present proposal presents an innovative tool, that can help to improve this situation and thus increase the potential benefits of hadron therapy. This project focuses on a portable device, that can simultaneously image both gamma-rays and thermal neutrons, which are ineluctably produced during the treatment. On one hand, imaging thermal neutrons may help to quantify more reliably the secondary neutron dose received by the patient during therapy. Complementary gamma-ray imaging is accomplished with the same apparatus by means of electronic collimation, thus enabling real-time assessment of the ion-range. In terms of gamma-vision, the system has been recently tested in pre-clinical conditions at CNA-Seville and HIT-Heidelberg. This POC project aims therefore at demonstrating the additional neutron-vision capability, thereby elevating the full GNVision system to TRL6, and addressing its commercial viability in the health-sector.

Champ scientifique (EuroSciVoc)

Programme(s)

Thème(s)

Régime de financement

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) ERC-2022-POC2

Voir tous les projets financés au titre de cet appel

Institution d’accueil

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Contribution nette de l'UE
€ 150 000,00
Coût total
Aucune donnée

Bénéficiaires (1)